195 related articles for article (PubMed ID: 31119725)
1. Survey on use of antenatal magnesium sulphate for fetal neuroprotection prior to preterm birth in Australia and New Zealand - Ongoing barriers and enablers.
Gatman K; May R; Crowther C
Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):44-48. PubMed ID: 31119725
[TBL] [Abstract][Full Text] [Related]
2. Nonreceipt of antenatal magnesium sulphate for fetal neuroprotection at the Women's and Children's Hospital, Adelaide 2010-2013.
Siwicki K; Bain E; Bubner T; Ashwood P; Middleton P; Crowther CA
Aust N Z J Obstet Gynaecol; 2015 Jun; 55(3):233-8. PubMed ID: 26084194
[TBL] [Abstract][Full Text] [Related]
3. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection.
Magee L; Sawchuck D; Synnes A; von Dadelszen P; ;
J Obstet Gynaecol Can; 2011 May; 33(5):516-529. PubMed ID: 21639972
[TBL] [Abstract][Full Text] [Related]
4. No. 376-Magnesium Sulphate for Fetal Neuroprotection.
Magee LA; De Silva DA; Sawchuck D; Synnes A; von Dadelszen P
J Obstet Gynaecol Can; 2019 Apr; 41(4):505-522. PubMed ID: 30879485
[TBL] [Abstract][Full Text] [Related]
5. Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: a study using the theoretical domains framework.
Bain E; Bubner T; Ashwood P; Van Ryswyk E; Simmonds L; Reid S; Middleton P; Crowther CA
BMC Pregnancy Childbirth; 2015 Aug; 15():176. PubMed ID: 26283623
[TBL] [Abstract][Full Text] [Related]
6. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis.
Crowther CA; Middleton PF; Voysey M; Askie L; Duley L; Pryde PG; Marret S; Doyle LW;
PLoS Med; 2017 Oct; 14(10):e1002398. PubMed ID: 28976987
[TBL] [Abstract][Full Text] [Related]
7. Working to improve survival and health for babies born very preterm: the WISH project protocol.
Crowther CA; Middleton PF; Bain E; Ashwood P; Bubner T; Flenady V; Morris J; McIntyre S;
BMC Pregnancy Childbirth; 2013 Dec; 13():239. PubMed ID: 24354790
[TBL] [Abstract][Full Text] [Related]
8. Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol.
Crowther CA; Middleton PF; Wilkinson D; Ashwood P; Haslam R;
BMC Pregnancy Childbirth; 2013 Apr; 13():91. PubMed ID: 23570677
[TBL] [Abstract][Full Text] [Related]
9. A prospective audit of the adherence to a new magnesium sulphate guideline for the neuroprotection of infants born less than 30 weeks' gestation.
Tan YH; Groom KM
Aust N Z J Obstet Gynaecol; 2015 Feb; 55(1):90-3. PubMed ID: 25307153
[TBL] [Abstract][Full Text] [Related]
10. Translating antenatal magnesium sulphate neuroprotection for infants born <28 weeks' gestation into practice: A geographical cohort study.
Doyle LW; Spittle AJ; Olsen JE; Kwong A; Boland RA; Lee KJ; Anderson PJ; Cheong JLY;
Aust N Z J Obstet Gynaecol; 2021 Aug; 61(4):513-518. PubMed ID: 33528040
[TBL] [Abstract][Full Text] [Related]
11. [Neuroprotection for preterm infants with antenatal magnesium sulphate].
Marret S; Ancel PY
J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1418-1433. PubMed ID: 28166926
[TBL] [Abstract][Full Text] [Related]
12. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.
Doyle LW; Crowther CA; Middleton P; Marret S; Rouse D
Cochrane Database Syst Rev; 2009 Jan; (1):CD004661. PubMed ID: 19160238
[TBL] [Abstract][Full Text] [Related]
13. Magnesium sulphate for preventing preterm birth in threatened preterm labour.
Crowther CA; Brown J; McKinlay CJ; Middleton P
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD001060. PubMed ID: 25126773
[TBL] [Abstract][Full Text] [Related]
14. Implementation of a clinical practice guideline for antenatal magnesium sulphate for neuroprotection in Australia and New Zealand.
Bain E; Bubner T; Ashwood P; Crowther CA; Middleton P;
Aust N Z J Obstet Gynaecol; 2013 Feb; 53(1):86-9. PubMed ID: 23106226
[TBL] [Abstract][Full Text] [Related]
15. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada.
De Silva DA; Synnes AR; von Dadelszen P; Lee T; Bone JN; ; Magee LA
Implement Sci; 2018 Jan; 13(1):8. PubMed ID: 29325592
[TBL] [Abstract][Full Text] [Related]
16. Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis.
Wolf HT; Huusom LD; Henriksen TB; Hegaard HK; Brok J; Pinborg A
BJOG; 2020 Sep; 127(10):1180-1188. PubMed ID: 32237069
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unit.
Ow LL; Kennedy A; McCarthy EA; Walker SP
Aust N Z J Obstet Gynaecol; 2012 Aug; 52(4):356-60. PubMed ID: 22515404
[TBL] [Abstract][Full Text] [Related]
18. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial.
Wolf HT; Brok J; Henriksen TB; Greisen G; Salvig JD; Pryds O; Hedegaard M; Weber T; Hegaard HK; Pinborg A; Huusom LD;
BJOG; 2020 Sep; 127(10):1217-1225. PubMed ID: 32237024
[TBL] [Abstract][Full Text] [Related]
19. Effect of antenatal magnesium sulphate on MRI biomarkers of white matter development at term equivalent age: The MagNUM Study.
Poppe T; Thompson B; Boardman JP; Bastin ME; Alsweiler J; Deib G; Harding JE; Crowther CA;
EBioMedicine; 2022 Apr; 78():103923. PubMed ID: 35331677
[TBL] [Abstract][Full Text] [Related]
20. Intrapartum magnesium sulfate is associated with neuroprotection in growth-restricted fetuses.
Stockley EL; Ting JY; Kingdom JC; McDonald SD; Barrett JF; Synnes AR; Monterrosa L; Shah PS; ; ;
Am J Obstet Gynecol; 2018 Dec; 219(6):606.e1-606.e8. PubMed ID: 30240651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
